|M10317||LNP023 hydrochloride (Iptacopan HCl)||Iptacopan (LNP023) hydrochloride is a first-in-class orally bioavailable, highly potent and selective complement factor B inhibitor with an IC50 value of 10 nM.|
|M10145||Danicopan (ALXN2040)||Danicopan (ALXN2040; ACH-4471; ACH-0144471) is a highly potent, orally active Factor D inhibitor.|
|M10140||TLQP-21 TFA||TLQP-21 is a VGF-derived peptide, which protects cerebellar granule cells (CGCs) from serum and potassium deprivation-induced apoptosis and increases energy expenditure and prevents early phase diet-induced diabetes.|
|M10114||PMX 205 Trifluoroacetate||PMX 205 Trifluoroacetate is a potent complement antagonist of C5a (C5aR; CD88) receptor.|
|M9199||Avacopan||Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor inhibitor with an IC50 of 0.1 nM.|
|M8983||Compstatin||Compstatinis is a 13-residue cyclic peptide, binds to complement component C3 and inhibits complement activation with IC50 of 12 μM. Compstatin exhibits exclusive specificity for primate C3s and does not bind either to C3s from lower mammalian species or to two structural homologs of C3, human C4 and C5.|
|M1598||Eculizumab||Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.